Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,995 JPY | -4.13% | +23.00% | +34.21% |
Apr. 30 | Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis | CI |
Apr. 30 | PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.74 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.21% | 1.69B | B- | ||
-1.43% | 104B | B+ | ||
+8.96% | 105B | B+ | ||
+4.40% | 22.94B | B | ||
-12.15% | 22.34B | B+ | ||
-4.36% | 19.25B | A- | ||
-39.98% | 17.08B | A- | ||
-10.04% | 16.96B | B | ||
+6.79% | 14.16B | C+ | ||
+38.61% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4587 Stock
- Ratings PeptiDream Inc.